Liabilities, Current of ABVC BIOPHARMA, INC. from 30 Sep 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Summary
ABVC BIOPHARMA, INC. quarterly Liabilities, Current in USD history and change rate from 30 Sep 2010 to 30 Sep 2025.
  • ABVC BIOPHARMA, INC. Liabilities, Current for the quarter ending 30 Sep 2025 was $6,507,520, a 4.2% increase year-over-year.
Source SEC data
View on sec.gov
Liabilities, Current, Quarterly (USD)
Liabilities, Current, YoY Quarterly Change (%)

ABVC BIOPHARMA, INC. Quarterly Liabilities, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $6,507,520 +$260,609 +4.2% 30 Sep 2025 10-Q 03 Nov 2025 2025 Q3
Q2 2025 $6,532,514 +$285,603 +4.6% 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $6,730,739 +$553,033 +9% 31 Mar 2025 10-Q 30 Apr 2025 2025 Q1
Q4 2024 $6,557,461 +$455,572 +7.5% 31 Dec 2024 10-Q 03 Nov 2025 2025 Q3
Q3 2024 $6,246,911 +$883,835 +16% 30 Sep 2024 10-Q 03 Nov 2025 2025 Q3
Q2 2024 $6,246,911 +$474,056 +8.2% 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $6,177,706 +$1,102,770 +22% 31 Mar 2024 10-Q 30 Apr 2025 2025 Q1
Q4 2023 $6,101,889 +$558,261 +10% 31 Dec 2023 10-K 15 Apr 2025 2024 FY
Q3 2023 $5,363,076 +$1,468,766 +38% 30 Sep 2023 10-Q 15 Nov 2023 2023 Q3
Q2 2023 $5,772,855 +$2,126,991 +58% 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $5,074,936 +$1,411,238 +39% 31 Mar 2023 10-Q 15 May 2023 2023 Q1
Q4 2022 $5,543,628 +$1,851,316 +50% 31 Dec 2022 10-K 13 Mar 2024 2023 FY
Q3 2022 $3,894,310 +$455,430 +13% 30 Sep 2022 10-Q 14 Nov 2022 2022 Q3
Q2 2022 $3,645,864 -$730,168 -17% 30 Jun 2022 10-Q 15 Aug 2022 2022 Q2
Q1 2022 $3,663,698 -$1,002,602 -21% 31 Mar 2022 10-Q 16 May 2022 2022 Q1
Q4 2021 $3,692,312 -$1,152,079 -24% 31 Dec 2021 10-K 31 Mar 2023 2022 FY
Q3 2021 $3,438,880 -$2,606,667 -43% 30 Sep 2021 10-Q 15 Nov 2021 2021 Q3
Q2 2021 $4,376,032 -$3,198,279 -42% 30 Jun 2021 10-Q 12 Aug 2021 2021 Q2
Q1 2021 $4,666,300 -$2,988,301 -39% 31 Mar 2021 10-Q 10 May 2021 2021 Q1
Q4 2020 $4,844,391 -$1,969,802 -29% 31 Dec 2020 10-K 31 Mar 2022 2021 FY
Q3 2020 $6,045,547 +$167,623 +2.9% 30 Sep 2020 10-Q 17 Nov 2020 2020 Q3
Q2 2020 $7,574,311 -$2,533,321 -25% 30 Jun 2020 10-Q 14 Aug 2020 2020 Q2
Q1 2020 $7,654,601 -$4,780,554 -38% 31 Mar 2020 10-Q 29 Jun 2020 2020 Q1
Q4 2019 $6,814,193 -$4,173,593 -38% 31 Dec 2019 10-K 16 Mar 2021 2020 FY
Q3 2019 $5,877,924 +$1,399,393 +31% 30 Sep 2019 10-Q 18 Nov 2019 2019 Q3
Q2 2019 $10,107,632 +$5,773,955 +133% 30 Jun 2019 10-Q 09 Aug 2019 2019 Q2
Q1 2019 $12,435,155 31 Mar 2019 10-Q 28 May 2019 2019 Q1
Q4 2018 $10,987,786 +$6,587,539 +150% 31 Dec 2018 10-K 15 May 2020 2019 FY
Q3 2018 $4,478,531 30 Sep 2018 10-Q 14 Nov 2018 2018 Q3
Q2 2018 $4,333,677 30 Jun 2018 10-Q 20 Aug 2018 2018 Q2
Q4 2017 $4,400,247 31 Dec 2017 10-K 15 Apr 2019 2018 FY
Q3 2015 $39,150 +$5,120 +15% 30 Sep 2015 10-Q 23 Feb 2016 2016 Q1
Q2 2015 $37,400 30 Jun 2015 10-Q 19 Aug 2015 2015 Q3
Q1 2015 $35,900 31 Mar 2015 10-Q 05 Jun 2015 2015 Q2
Q4 2014 $35,060 31 Dec 2014 10-Q 17 Apr 2015 2015 Q1
Q3 2014 $34,030 $0 0% 30 Sep 2014 10-Q 19 Aug 2015 2015 Q3
Q3 2013 $34,030 -$1,912,056 -98% 30 Sep 2013 10-Q 17 Apr 2015 2015 Q1
Q1 2013 $2,092,258 +$417,533 +25% 31 Mar 2013 10-Q 16 Apr 2015 2013 Q2
Q4 2012 $2,066,722 +$388,814 +23% 31 Dec 2012 10-Q 16 Apr 2015 2013 Q1
Q3 2012 $1,946,086 +$113,017 +6.2% 30 Sep 2012 10-K 16 Apr 2015 2013 FY
Q2 2012 $1,827,485 +$68,996 +3.9% 30 Jun 2012 10-Q/A 20 Aug 2012 2012 Q3
Q1 2012 $1,674,725 31 Mar 2012 10-Q 15 May 2012 2012 Q2
Q4 2011 $1,677,908 31 Dec 2011 10-Q 21 Feb 2012 2012 Q1
Q3 2011 $1,833,069 -$1,454,683 -44% 30 Sep 2011 10-K 15 Apr 2015 2012 FY
Q2 2011 $1,758,489 30 Jun 2011 10-Q/A 08 Sep 2011 2011 Q3
Q3 2010 $3,287,752 30 Sep 2010 10-K/A 28 Dec 2011 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.